Roberts Sarah C M, Liu Guodong, Terplan Mishka
From the Advancing New Standards in Reproductive Health, Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, Oakland, CA (SCMR); Department of Public Health Sciences and of Pediatrics, Penn State College of Medicine, Hershey, PA (GL); and Friends Research Institute, Baltimore, MD (MT).
J Addict Med. 2025;19(1):41-46. doi: 10.1097/ADM.0000000000001372. Epub 2024 Sep 4.
Although safety and effectiveness of medications for alcohol use disorder (AUD) are well established for adults, literature on these medications in pregnancy is limited. Given known adverse effects of untreated AUD during pregnancy, clinicians and researchers have recently begun to call for reconsidering use of medications for AUD in pregnancy. Thus, we sought to estimate the proportion of birthing people with an alcohol-related diagnosis who received a prescription for medication related to AUD treatment.
Data were from Meritive MarketScan, a national private insurance claims database. The study cohort included birthing people aged 25-50 who gave birth to a singleton in the United States between 2006 and 2019 and were matched with an infant. Variables included an alcohol-related diagnosis within a year of birth and receiving a prescription for a medication related to AUD treatment. We calculated proportions with alcohol-related diagnoses who received any AUD medication and each medication type.
Of 1,432,979 birthing person-infant dyads, 2517 (0.18%) had an alcohol-related diagnosis. Of those with an alcohol-related diagnosis, 8.70% (n = 219) received any medication. The most common was gabapentin (4.69%, n = 118), with benzodiazepines for withdrawal as the second most common (2.19%, n = 55). Approximately 2% received naltrexone (1.91%, n = 48) and/or disulfiram (1.39%, n = 35); 0.56% (n = 14) received acamprosate. No one with an alcohol-related diagnosis received phenobarbital. Almost all medications were received postpartum.
Very few pregnant/postpartum people with alcohol-related diagnoses are prescribed medications related to AUD treatment. Research is needed to examine whether benefits of these medications during pregnancy outweigh harms.
虽然用于治疗酒精使用障碍(AUD)的药物在成人中的安全性和有效性已得到充分证实,但关于这些药物在孕期使用的文献有限。鉴于孕期未治疗的AUD已知的不良影响,临床医生和研究人员最近开始呼吁重新考虑在孕期使用治疗AUD的药物。因此,我们试图估计患有酒精相关诊断的分娩者中接受与AUD治疗相关药物处方的比例。
数据来自Meritive MarketScan,这是一个全国性的私人保险理赔数据库。研究队列包括2006年至2019年在美国生育单胎、年龄在25至50岁之间且与一名婴儿匹配的分娩者。变量包括出生一年内的酒精相关诊断以及接受与AUD治疗相关药物的处方。我们计算了患有酒精相关诊断且接受任何AUD药物和每种药物类型的比例。
在1,432,979对分娩者 - 婴儿二元组中,2517例(0.18%)有酒精相关诊断。在那些有酒精相关诊断的人中,8.70%(n = 219)接受了任何药物治疗。最常用的是加巴喷丁(4.69%,n = 118),用于戒酒的苯二氮䓬类药物是第二常用的(2.19%,n = 55)。约2%的人接受了纳曲酮(1.91%,n = 48)和/或双硫仑(1.39%,n = 35);0.56%(n = 14)接受了阿坎酸。没有一个有酒精相关诊断的人接受苯巴比妥。几乎所有药物都是在产后使用的。
很少有患有酒精相关诊断的孕妇/产后妇女被开具与AUD治疗相关的药物。需要进行研究以检查这些药物在孕期的益处是否大于危害。